Quarterly Activities/Appendix 4C Cash Flow Report

Key points

• Clarity Pharmaceuticals maintains a strong cash position of $178.3 million as of June 30, 2026
• Significant clinical progress with SAR-bisPSMA and SARTATE, including FDA Fast Track Designations
• Expansion of manufacturing capabilities with Nucleus RadioPharma and SpectronRx
• Addition of Allison Rossiter to the Board as an Independent Non-Executive Director
• Dr. Colin Biggin steps down from Executive Director role, continuing as Chief Operating Officer

Full summary

Clarity Pharmaceuticals Ltd, an Australian clinical-stage radiopharmaceutical company, has released its Quarterly Activity Report for the three months ending June 30, 2026. The company remains well-funded with a cash position of $178.3 million, enabling continued progression towards commercialization. Clarity has made strides in its clinical trials, with data from SAR-bisPSMA and SARTATE presented at prestigious conferences. Notably, SAR-bisPSMA has received three US FDA Fast Track Designations, underscoring its potential to address unmet needs in prostate cancer treatment. The company has also expanded its manufacturing capabilities with agreements with Nucleus RadioPharma and SpectronRx, enhancing its supply network. Additionally, Clarity has welcomed Allison Rossiter to its Board as an Independent Non-Executive Director, while Dr. Colin Biggin transitions from his Executive Director role to Chief Operating Officer.